Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) (S.A.E) (EGX:RMDA)
Egypt flag Egypt · Delayed Price · Currency is EGP
5.77
-0.03 (-0.52%)
At close: Aug 5, 2026

EGX:RMDA Cash Flow Statement

Millions EGP. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
318.98298.46387.37244.86245.68181.09
Depreciation & Amortization
93.1992.2383.4372.8865.4846.18
Loss (Gain) From Sale of Assets
-1.13-0.15-0.01-0.140.130.72
Asset Writedown & Restructuring Costs
-0.382.562.51---
Stock-Based Compensation
31.8415.9516.2917.7717.85-
Provision & Write-off of Bad Debts
103.2104.811.443.813.640.11
Other Operating Activities
76.8460.949.242.42-8.44-10.39
Change in Accounts Receivable
-982.13-741.17-218.62-374.86-243.64-29.45
Change in Inventory
122.19-273.6-439.5130.97-88.5947.58
Change in Accounts Payable
96.3752.98276.3816.9768.5931.51
Change in Other Net Operating Assets
72.95343.33-435.45-59.17-31.35-25.99
Operating Cash Flow
-68.1-43.67-306.92-44.529.35241.35
Operating Cash Flow Growth
-----87.84%-

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-157.87-155.9-64.93-91.05-34.38-52.67
Sale of Property, Plant & Equipment
2.040.21.720.180.020.02
Sale (Purchase) of Intangibles
-123.68-594.95-1.71-162.44-93.9-185.53
Investment in Securities
77.01237.39120.66194.68167.4768.06
Other Investing Activities
35.57--93.84---
Investing Cash Flow
-166.95-513.26-38.09-58.6339.22-170.11

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Short-Term Debt Issued
-3,4341,9981,4211,2051,172
Total Debt Issued
3,2013,4341,9981,4211,2051,172
Short-Term Debt Repaid
--2,681-1,551-1,265-1,121-1,156
Long-Term Debt Repaid
--13.25-6.34-5.74-27.14-71.19
Total Debt Repaid
-2,781-2,694-1,558-1,271-1,149-1,228
Net Debt Issued (Repaid)
419.61740.47440.9149.7256.96-55.09
Issuance of Common Stock
1.881.883.232.11--
Repurchase of Common Stock
-----65.93-
Common Dividends Paid
-188.91-188.91-121.28-16.76-24.31-14.7
Financing Cash Flow
232.58553.44322.86135.07-33.28-69.79

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
5.5-24.8234.480.4217.22-0.19
Net Cash Flow
3.04-28.3212.3232.3752.511.26

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-225.98-199.57-371.85-135.54-5.03188.68
Free Cash Flow Growth
------
Free Cash Flow Margin
-5.26%-4.87%-13.43%-7.05%-0.34%15.14%
Free Cash Flow Per Share
-0.11-0.10-0.18-0.07-0.000.09
Levered Free Cash Flow
-331.76-834.46-552.55-381.77-108.98-7.86
Unlevered Free Cash Flow
-0.17-502.42-360.54-262.27-53.3249.03

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Interest Paid
513.94526.8294.66186.5284.8289.41
Cash Income Tax Paid
92.68101.8167.0760.6944.2928.91
Change in Working Capital
-690.62-618.46-817.2-386.09-29523.64